| __timestamp | Geron Corporation | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 16758000 | 22570000 |
| Thursday, January 1, 2015 | 17793000 | 24378000 |
| Friday, January 1, 2016 | 18761000 | 26621000 |
| Sunday, January 1, 2017 | 19287000 | 28653000 |
| Monday, January 1, 2018 | 18707000 | 37734000 |
| Tuesday, January 1, 2019 | 20893000 | 41884000 |
| Wednesday, January 1, 2020 | 25678000 | 64435000 |
| Friday, January 1, 2021 | 29665000 | 57483000 |
| Saturday, January 1, 2022 | 43628000 | 70062000 |
| Sunday, January 1, 2023 | 69135000 | 52790000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Ligand Pharmaceuticals Incorporated and Geron Corporation from 2014 to 2023. Over this period, Ligand Pharmaceuticals consistently outspent Geron Corporation, with an average SG&A expense of approximately $42.7 million annually, compared to Geron's $28 million. Notably, Ligand's expenses peaked in 2022 at $70 million, reflecting a strategic investment in growth initiatives. Meanwhile, Geron saw a significant increase in 2023, with expenses rising to $69 million, a 58% jump from the previous year. This surge may indicate a shift in Geron's operational strategy or an expansion effort. Understanding these trends provides valuable insights into how these companies allocate resources to drive innovation and maintain competitiveness in the biotech sector.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Geron Corporation
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Jazz Pharmaceuticals plc and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and Geron Corporation
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation
Breaking Down SG&A Expenses: Merus N.V. vs Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated vs Dynavax Technologies Corporation: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Geron Corporation or Wave Life Sciences Ltd.